AzTrials
AzTrials

High AltitudeNCT07804485

Assessment of Total Pulmonary Resistance sPAP/CO Between High Altitude HA vs. Sea Level LA in Healthy Individuals H

A study testing Descent from 2850m to sea level in people with High Altitude and Healthy Adult, run by Silvia Ulrich Somaini at 1 site in Switzerland.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

To study the effect of relocation from high altitude (Quito Ecuador: 2850m) to sea level on pulmonary resistance (sPAP/CO) and other hemodynamic outcomes in healthy individuals, who live permanently >2600m. Read more about this study

Who is it for?
Ages 18 to 80 yearsHealthy volunteers can take part
Conditions the study is for
High Altitude, Healthy Adult, Echocardiography
What is being tested?
Descent from 2850m to sea level
Could I receive a placebo?
No, everyone receives an active treatment
How many people
14 participants
Where
1 siteSwitzerland
Study dates
25 Sep 2026to 31 Dec 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Adults aged 18-80 years and of all genders
  • Permanent residence > 2600 m
  • healthy: no self-perceived cardiopulmonary disease limiting daily activities
  • written informed consent to participate in the study.

Who cannot join

  • Age <18 years or >80 years
  • People who cannot follow the study investigations
  • Participant permanently living < 2600m.
  • Participant who traveled and stayed overnight at altitudes <2000 m in the past 4 weeks.
  • any self-perceived cardiopulmonary disease limiting daily activities

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Silvia Ulrich, Prof. Dr. med. contact

+41442552220

silvia.ulrich@usz.ch

Michael Furian, Prof. Dr. sc. ETH contact

+41442552220

Switzerland1 site

  • University Hospital of Zurich

    Zurich, 8091

Other trials in Switzerland

About this study

Official title: Effect of a One-week Descent From 2850m to Sea Level and Re-ascent in Patients With Pulmonary Arterial Hypertension and Healthy Controls Permanently Living > 2600m on Pulmonary Hemodynamics, Exercise Capacity, Blood Oxygenation, Sleep Disordered Breathing and Further Outcomes

To study the effect of relocation from high altitude (Quito Ecuador: 2850m) to sea level on pulmonary resistance (sPAP/CO) and other hemodynamic outcomes in healthy individuals, who live permanently >2600m.

Read the detailed description

The aim of this research is to investigate the pulmonary resistance (sPAP/CO) by echocardiography and other hemodynamic outcomes before and after relocation (high altitude near their living altitude vs. sea level) in healthy individuals, who permanently live at high altitude over 2600m.

Being tested
Descent from 2850m to sea level
Keywords
Hypoxia, High altitude, Health, Echocardiography, Pulmonary resistance, Hemodynamics
Medical subject headings
Altitude Sickness, Hypoxia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Descent from 2850m to sea levelBehavioural

    Descent from 2850m to sea level with a stay for 7 days

Study groups in NCT07804485
Study groupRoleWhat they receive
Pulmonary resistance (sPAP/CO) at 2850m and at sea levelExperimentalMeasurement of pulmonary resistance (sPAP/CO) by echocardiography and other hemodynamic parameters near their resident altitude at 2850m followed by a descent from 2850m to sea level by bus with a stay for 7 days and again measurements by echocardiography
Receives: Behavioral: Descent from 2850m to sea level

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Pulmonary resistance (sPAP/CO) after 7 days at sea level

    Difference/change in sPAP/CO by echocardiography between 2850m and Day 5-7 at sea level in healthy individuals

    Measured: From high altitude (2850m) to day 5-7 at sea level

Secondary outcomes (21)

  1. Tricuspid regurgitation velocity TRV after 7 days at sea level

    Difference/change in tricuspid regurgitation velocity TRV between 2850m and Day 5-7 at sea level in healthy individuals

    Measured: From high altitude (2850m) to day 5-7 at sea level

  2. Cardiac output CO after 7 days at sea level

    Difference/change in cardiac output CO between 2850m and Day 5-7 at sea level in healthy individuals

    Measured: From high altitude (2850) to day 5-7 at sea level

  3. Tricuspid annular plan systolic excursion TAPSE after 7 days at sea level

    Difference/change in tricuspid annular plan systolic excursion TAPSE between 2850m and Day 5-7 at sea level in healthy individuals

    Measured: From high altitude (2850m) to day 5-7 at sea level

  4. Right ventricular strain after 7 days at sea level

    Difference/change in right ventricular strain between 2850m and day 5-7 at sea level in healthy individuals

    Measured: From high altitude (2850m) to Day 5-7 at sea level

  5. Right atrial pressure RAP after 7 days at sea level

    Difference/change in right atrial pressure RAP between 2850m and day 5-7 at sea level in healthy individuals

    Measured: From high altitude (2850m) to Day 5-7 at sea level

  6. Fractional area change FAC after 7 days at sea level

    Difference/change in fractional area change FAC between 2850m and day 5-7 at sea level in healthy individuals

    Measured: From high altitude (2850m) to Day 5-7 at sea level

  7. PaO2 after 7 days at sea level

    Difference/change in PaO2 (arterial blood gas analysis) between 2850m and sea level in healthy individuals

    Measured: From high altitude (2850) to day 7 at sea level

  8. PaCO2 after 7 days at sea level

    Difference/change in PaCO2 (arterial blood gas analysis) between 2850m and sea level in healthy individuals

    Measured: From high altitude (2850) to day 7 at sea level

  9. Hemoglobin after 7 days at sea level

    Difference/change in hemoglobin (arterial blood gas analysis) between 2850m and sea level in healthy individuals

    Measured: From high altitude (2850) to day 7 at sea level

  10. pH after 7 days at sea level

    Difference/change in pH (arterial blood gas analysis) between 2850m and sea level in healthy individuals

    Measured: From high altitude (2850) to day 7 at sea level

  11. Acclimatization-Effect of pulmonary resistance (sPAP/CO) at sea level

    Difference/change in pulmonary resistance (sPAP/CO) within a stay at sea level of 7 days (after relocation from high altitude) in healthy individuals

    Measured: From Day 2 to Day 5-7 at sea level

  12. Acclimatization-Effect of tricuspid regurgitation velocity TRV at sea level

    Difference/change in tricuspid regurgitation velocity TRV within a stay at sea level of 7 days (after relocation from high altitude) in healthy individuals

    Measured: From Day 2 to Day 5-7 at sea level

  13. Acclimatization-Effect of cardiac output CO at sea level

    Difference/change in cardiac output CO within a stay at sea level of 7 days (after relocation from high altitude) in healthy individuals

    Measured: From Day 2 to Day 5-7 at sea level

  14. Acclimatization-Effect of tricuspid annular plan systolic excursion TAPSE at sea level

    Difference/change in tricuspid annular plan systolic excursion TAPSE within a stay at sea level for 7 days (after relocation from high altitude) in healthy individuals

    Measured: From Day 2 to Day 5-7 at sea level

  15. Acclimatization-Effect of right ventricular strain at sea level

    Difference/change in right ventricular strain within a stay at sea level for 7 days (after relocation from high altitude) in healthy individuals

    Measured: From Day 2 to Day 5-7 at sea level

  16. Acclimatization-Effect of right atrial pressure RAP at sea level

    Difference/change in right atrial pressure RAP within a stay at sea level for 7 days (after relocation from high altitude) in healthy individuals

    Measured: From Day 2 to Day 5-7 at sea level

  17. Acclimatization-Effect of fractional area change FAC at sea level

    Difference/change in fractional area change FAC within a stay at sea level for 7 days (after relocation from high altitude) in healthy individuals

    Measured: From Day 2 to Day 5-7 at sea level

  18. Acclimatization-Effect of PaO2 at sea level

    Difference/change in PaO2 (arterial blood gas analysis) within a stay at sea level for 7 days (after relocation from high altitude) in healthy individuals

    Measured: From Day 2 to Day 7 at sea level

  19. Acclimatization-Effect of PaCO2 at sea level

    Difference/change in PaCO2 (arterial blood gas analysis) within a stay at sea level for 7 days (after relocation from high altitude) in healthy individuals

    Measured: From Day 2 to Day 7 at sea level

  20. Acclimatization-Effect of hemoglobin at sea level

    Difference/change in hemoglobin (arterial blood gas analysis) within a stay at sea level for 7 days (after relocation from high altitude) in healthy individuals

    Measured: From Day 2 to Day 7 at sea level

  21. Acclimatization-Effect of pH at sea level

    Difference/change in pH (arterial blood gas analysis) within a stay at sea level for 7 days (after relocation from high altitude) in healthy individuals

    Measured: From Day 2 to Day 7 at sea level

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Sep 2026
  2. Study start25 Sep 2026 (estimated)
  3. Primary completion4 Oct 2026 (estimated)
  4. Study completion31 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Model description
Healthy individuals living permanently \> 2600m around Quito (Ecuador) will be assessed at 2850m and after relocation to sea level
Masking
None (open label)
Enrolment
14 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07804485
Sponsor's protocol ID
Ec_HAvsLA_sPAP/CO_H
Status last verified
Aug 2026
First submitted
17 Aug 2026
Last updated
4 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Data will be provided upon request and based on a clear intention reviewed by an ethical review board.

Questions about this trial

What is this clinical trial studying?

A study testing Descent from 2850m to sea level in people with High Altitude and Healthy Adult, run by Silvia Ulrich Somaini at 1 site in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 4 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Silvia Ulrich, Prof. Dr. med. (+41442552220, silvia.ulrich@usz.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Pulmonary resistance (sPAP/CO) after 7 days at sea level (time frame: From high altitude (2850m) to day 5-7 at sea level). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07804485.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Sep 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in